Comparison between Product Characteristics and Decision Analysis Supporting Decision-Makers in Public Health-Related Choices: A Study Model Applied to Anti-HPV Vaccines

9 Pages Posted: 3 Jan 2008

See all articles by Giampiero Favato

Giampiero Favato

Institute of Leadership and Management in Health - Kingston University

Francesco Saverio Mennini

University of Rome Tor Vergata

Andrea Monorchio

University of Siena - Faculty of Political Science

Emilio Mortilla

University of California, Berkeley

Date Written: January 1, 2008

Abstract

Vaccines for the prevention of pathologies caused by Human Papillomavirus (HPV) are undoubtedly considered among the most advanced forms of biotechnological innovation. At present, two different vaccines are available: the bivalent vaccine, targeting the HPV-16 and 18 strains, and the quadrivalent vaccine, which targets the HPV-6, 11, 16 and 18 strains.

Observing the impact projections analysis, obtainable on the basis of data published in various studies, it is clear that a reduction of 10.0 euros, resulting from the ex-factory price differential of the two vaccines (in favour of the bivalent) hardly compensate for the considerable increase of the expenditure related to the failure to prevent HPV-induced outcomes, such as abnormal Pap-tests, colposcopies, low and high-grade precancerous lesions, in situ carcinomas, cervical carcinomas, vulvar dysplastic lesions, vaginal dysplastic lesions and genital warts.

A mere difference in ex-factory price should not be the only determinant of the vaccine's choice, in the light of the incremental prevention against cervical carcinoma caused by HPV-18 and vulvar carcinoma, and the avoidable risk of onset of genital warts.

Keywords: spc, decision,analysis,HPV,vaccines,cost

JEL Classification: I11,I18

Suggested Citation

Favato, Giampiero and Mennini, Francesco Saverio and Monorchio, Andrea and Mortilla, Emilio, Comparison between Product Characteristics and Decision Analysis Supporting Decision-Makers in Public Health-Related Choices: A Study Model Applied to Anti-HPV Vaccines (January 1, 2008). Available at SSRN: https://ssrn.com/abstract=1080089 or http://dx.doi.org/10.2139/ssrn.1080089

Giampiero Favato (Contact Author)

Institute of Leadership and Management in Health - Kingston University ( email )

Kingston Hill
Kingston upon Thames
Surrey KT2 7LB
United Kingdom

Francesco Saverio Mennini

University of Rome Tor Vergata ( email )

Via di Tor Vergata
Rome, Lazio 00133
Italy

Andrea Monorchio

University of Siena - Faculty of Political Science ( email )

Siena
Italy

Emilio Mortilla

University of California, Berkeley ( email )

310 Barrows Hall
Berkeley, CA 94720
United States

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
134
Abstract Views
1,554
Rank
385,913
PlumX Metrics